Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[3] Soerjomataram I(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[4] Cunningham D(2014)Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Eur J Surg Oncol 40 584-591

[5] Allum WH(1995)Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients Lancet 345 745-748

[6] Stenning SP(1996)Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial The Surgical Cooperative Group Lancet 347 995-999

[7] Macdonald JS(2018)Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial Lancet Gastroenterol Hepatol 3 460-468

[8] Smalley SR(2016)Long-term survival in patients with postoperative intra-abdominal infectious complications after curative gastrectomy for gastric cancer: A propensity score matching analysis Ann Surg Oncol 23 809-816

[9] Benedetti J(2014)Prognostic significance of complications after curative surgery for gastric cancer Ann Surg Oncol 21 891-898

[10] Waddell T(2013)Clinicopathological characteristics and survival difference between gastric stump carcinoma and primary upper third gastric cancer J Gastrointest Surg 17 313-318

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[3] Soerjomataram I(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[4] Cunningham D(2014)Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Eur J Surg Oncol 40 584-591

[5] Allum WH(1995)Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients Lancet 345 745-748

[6] Stenning SP(1996)Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial The Surgical Cooperative Group Lancet 347 995-999

[7] Macdonald JS(2018)Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial Lancet Gastroenterol Hepatol 3 460-468

[8] Smalley SR(2016)Long-term survival in patients with postoperative intra-abdominal infectious complications after curative gastrectomy for gastric cancer: A propensity score matching analysis Ann Surg Oncol 23 809-816

[9] Benedetti J(2014)Prognostic significance of complications after curative surgery for gastric cancer Ann Surg Oncol 21 891-898

[10] Waddell T(2013)Clinicopathological characteristics and survival difference between gastric stump carcinoma and primary upper third gastric cancer J Gastrointest Surg 17 313-318